more_reports

Clive Maund

CliveMaund.com


Clive Maund has been president of www.clivemaund.com, a successful resource sector website, since its inception in 2003. He has 30 years' experience in technical analysis and has worked for banks, commodity brokers and stockbrokers in the City of London. He holds a Diploma in Technical Analysis from the UK Society of Technical Analysts.

07/28/2022 – NEWSLETTER: Algernon Pharmaceuticals Inc.

Recent Articles about Algernon Pharmaceuticals Inc.

Could This Stock Be the Next Bellus Cough Treatment? 07/17/2024

Technical Analyst Clive Maund shares an extensive overview of Algernon Pharmaceuticals Inc. (AGN:CSE; AGNPF:OTCQB; AGN0:XFRA) to explain why he believes it is a Strong Buy.

Tech. Analyst Says Pharma Co. Is at a Favorable Risk/Reward Ratio 12/28/2022

Technical analyst Clive Maund reviews Algernon Pharmaceuticals Inc.'s 6-month, 3-year, and 9-year charts to tell you whether you should be interested in this pharma company.

Expert Says Buy Pharma Co. Stock 'as Soon as Possible' 10/25/2022

Algernon Pharmaceuticals has entered into a clinical trial agreement with Yale and caught expert Clive Maund's attention. In light of this, Maund reviews the company's chart to tell you when he believes you should buy its stock.

Expert Says Life Science Co.'s Technical Setup Is 'Exceptionally Positive and Keeps Getting Better' 09/13/2022

Expert Clive Maund reviews the 6-month and 15-month charts for Awakn Life Sciences Corp. to explain why he thinks this company's technical setup is exceptionally positive.

Expert Sees Even More 'Good News' From Pharma Co. 08/23/2022

Expert Clive Maund reviews the latest news with Algernon Pharmaceuticals Inc., including the recent successful closing of its financing.

Expert Says Biotech Co. Is a ‘Strong Buy’ After Phase 2 Study 08/02/2022

Expert Clive Maund gives his assessment of biotech Algernon Pharmaceuticals Inc. after its Phase 2 study of Ifenprodil.